Hereβs the structured reference for Bedaquiline Tablet 100 mg π
π Bedaquiline Tablet 100 mg
π Description:
- Bedaquiline is a novel diarylquinoline antimycobacterial drug.
- It specifically inhibits mycobacterial ATP synthase enzyme, blocking energy production in Mycobacterium tuberculosis.
- Effective against drug-resistant tuberculosis (MDR-TB & XDR-TB).
π Prescription / Indications:
- Used only as part of combination therapy for:
- Multidrug-resistant tuberculosis (MDR-TB)
- Extensively drug-resistant tuberculosis (XDR-TB)
- Cases where other regimens are ineffective or not tolerated.
πΏ Nature / Drug Class:
- Antimycobacterial agent
- Diarylquinoline class
β Advantages:
- Provides a new mechanism of action compared to other TB drugs.
- Effective against resistant strains.
- Shortens treatment duration in resistant TB regimens.
β οΈ Precautions:
Contraindications:
- Hypersensitivity to bedaquiline.
Use with caution in:
- Cardiac patients β may cause QT prolongation (ECG monitoring needed).
- Liver impairment β hepatotoxicity risk.
- Patients taking other QT-prolonging drugs (fluoroquinolones, clofazimine, azoles).
Adverse Effects:
- Nausea, headache, arthralgia.
- Hepatotoxicity (monitor LFTs).
- QT prolongation (ECG monitoring essential).
- Chest pain, hemoptysis (rare).
π Dosage (Adults):
- Week 1β2: 400 mg once daily with food.
- Week 3β24: 200 mg three times per week (with at least 48 hours between doses).
- Always in combination with other effective TB drugs.
- Max duration: 24 weeks.
π¦ Common Packaging:
- Tablets: 100 mg
- Usually supplied in blister packs or bottles.
βοΈ Storage Conditions:
- Store below 30Β°C.
- Keep in original container, protect from moisture.

